Inhibition of monoamine oxidase B reduces atherosclerosis and fatty liver in mice
Clinical Science · 2023
DOI: 10.1042/cs20220477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2023. Verfasst von Shu-Huei Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Non-alcoholic Fatty Liver Disease, Atherosclerosis, Hypercholesterolemia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Oxidative stress is vital for pathophysiology of atherosclerosis and non-alcoholic fatty liver disease (NAFLD). Monoamine oxidase (MAO) is an important source of oxidative stress in the vascular system and liver. However, the effect of MAO inhibition on atherosclerosis and NAFLD has not been explored. In the present study, MAO A and B expressions were increased in atherosclerotic plaques in human and apolipoprotein E (ApoE)-deficient mice. Inhibition of MAO B (by deprenyl), but not MAO A (by clorgyline), reduced the atheroma area in the thoracic aorta and aortic sinus in ApoE-deficient mice fed the cholesterol-enriched diet for 15 weeks. MAO B inhibition attenuated oxidative stress, expression of adhesion molecules, production of inflammatory cytokines, and macrophage infiltration in atherosclerotic plaques and decreased plasma triglyceride and low-density lipoprotein (LDL) cholesterol concentrations. MAO B inhibition had no therapeutic effect on restenosis in the femoral artery wire-induced injury model in C57BL/6 mice. In the NAFLD mouse model, MAO B inhibition reduced lipid droplet deposition in the liver and hepatic total cholesterol and triglyceride levels in C57BL/6 mice fed high-fat diets for 10 weeks. Key enzymes for triglyceride and cholesterol biosynthesis (fatty acid synthase and 3-hydroxy-3-methylglutaryl-CoA reductase, HMGCR) and inflammatory markers were inhibited, and cholesterol clearance was up-regulated (increased LDL receptor expression and reduced proprotein convertase subtilisin/kexin type 9, PCSK9, expression) by MAO B inhibition in the liver. These results were also demonstrated in the HepG2 liver cell model. Our data suggest that MAO B inhibition is a potential and novel treatment for atherosclerosis and NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.
- Medical coder, Get Heal, Inc., CA, U.S.A.
- Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
- School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
ORCID-Profile: Hung-Yuan Li
Zitieren
APA
Wang, S. H., Tsai, F. C., Lin, H. H., Yu, T. Y., Kuo, C. H., Li, H. Y., & Lin, M. S. (2023). Inhibition of monoamine oxidase B reduces atherosclerosis and fatty liver in mice. Clinical Science. https://doi.org/10.1042/cs20220477
Vancouver
Wang SH, Tsai FC, Lin HH, Yu TY, Kuo CH, Li HY, et al. Inhibition of monoamine oxidase B reduces atherosclerosis and fatty liver in mice. Clinical Science. 2023. doi:10.1042/cs20220477
BibTeX
@article{Wang2023,
author = {Wang, Shu-Huei and Tsai, Feng-Chiao and Lin, Heng-Huei and Yu, Tse-Ya and Kuo, Chun-Heng and Li, Hung-Yuan and Lin, Mao-Shin},
title = {Inhibition of monoamine oxidase B reduces atherosclerosis and fatty liver in mice},
journal = {Clinical Science},
year = {2023},
doi = {10.1042/cs20220477}
}
EUVIMED